Merck Sharpe and Dohme reports ‘strong’ Q2 results

Merck Sharpe and Dohme has published its financial report for the second quarter of 2010, highlighting the strength of its performance since the merger with Schering-Plough.

The company’s sales for the quarter showed a pronounced year-on-year increase to $11.3 billion (7.1 billion pounds), compared to $5.9 billion in Q2 2009, which took place before the merger.

Key brands such as Januvia, Janumet, Remicade and Temodar demonstrated strong sales performances, while regulatory clearance was granted to newer treatments such as Dulera and Brinavess.

Richard Clark, chairman and chief executive officer of Merck Sharpe and Dohme, stated that the company’s first-half achievements have positioned it well to achieve its long-term aims.

He said: “Our strong bottom-line performance in the second quarter demonstrates Merck’s continued success in executing our post-merger strategy.”

Last month, Merck Sharpe and Dohme published new data from a study into awareness of Aids issues in the UK and Europe, revealing how a lack of knowledge can affect treatment success.